FDA warned globalpharmacyplus.com in Canada for selling unapproved and misbranded prescription drugs to U.S. consumers online.
What happened
FDA reviewed the website www.globalpharmacyplus.com and found it offered prescription drugs for sale to U.S. consumers without FDA-approved applications and with labeling that lacked adequate directions and warnings. The examples cited were Molnunat 200 (molnupiravir) for COVID-19 and transplant drugs CellCept 500mg (mycophenolate mofetil) and Tacrolimus Capsules Tacrograf – 0.5.
What FDA found
The website offered unapproved new drugs for sale to U.S. consumers without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website offered molnupiravir as Molnunat 200 with claims to treat COVID-19, but FDA had not approved or authorized that product.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website offered mycophenolate mofetil as CellCept 500mg without an FDA-approved application, while FDA-approved versions have a REMS (a drug safety program) and a boxed warning (FDA’s strongest warning).
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website offered tacrolimus as Tacrolimus Capsules Tacrograf – 0.5 without an FDA-approved application, and oral tacrolimus is a narrow therapeutic index drug (small dose differences can be dangerous).
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The prescription drugs’ labeling lacked adequate directions for use by a layperson, making them misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; section 301(a) [21 U.S.C. § 331(a)]The drugs’ labeling lacked adequate warnings, including for mycophenolate, so important safety measures for FDA-approved versions could be bypassed.
FD&C Act section 502(f)(2) [21 U.S.C. § 352(f)(2)]
What FDA wants
FDA asks the company to stop offering any unapproved or misbranded drugs for sale to U.S. consumers and to respond in writing within 15 working days with the steps taken to correct the violations and prevent recurrence.
Who should pay attention
- online pharmacies that ship to U.S. patients
- sellers of COVID-19 treatment products
- transplant drug suppliers and pharmacists
This is a summary. Read the original letter on fda.gov.